<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572649</url>
  </required_header>
  <id_info>
    <org_study_id>PKD11475</org_study_id>
    <secondary_id>2011-004584-67</secondary_id>
    <secondary_id>U1111-1124-3136</secondary_id>
    <nct_id>NCT01572649</nct_id>
  </id_info>
  <brief_title>Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To investigate the effects of two single subcutaneous lixisenatide doses (5 and 10 µg) as&#xD;
      compared to placebo in reducing postprandial glucose (PPG) in type 2 diabetic paediatric&#xD;
      population (10-17 years old) and adults as controls&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      - To evaluate in both paediatric and adult populations:&#xD;
&#xD;
        -  the blood levels of lixisenatide (pharmacokinetic) parameters in plasma after single&#xD;
           subcutaneous ascending doses&#xD;
&#xD;
        -  the maximum post-prandial glucose excursion, and on the changes in insulin, C-peptide&#xD;
           and glucagon plasma concentrations following a standardized breakfast&#xD;
&#xD;
        -  safety and tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study for each patient is planned between 4 and 7 weeks including a&#xD;
      screening period (25 to 30 days), 3 treatment periods 1-7 days apart, each period lasting&#xD;
      only one day (Day 1) and an end-of-study visit between 1 to 7 days after the last dose&#xD;
      administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GLU-AUC 0:30-4:30h: area under the plasma glucose concentration time profile from time of the standardized breakfast start (30 min after IMP injection and pre-meal plasma glucose) until 4 hours later subtracting the pre-meal value</measure>
    <time_frame>D1 at each period up to 4h30 after study drug injection (8 timepoints)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: lixisenatide plasma concentration</measure>
    <time_frame>0 (predose), 30 min, 1h, 1h30, 2h30, 3h30, 4h30 and 6h30 post-dose at D1 of each study period (8 timepoints)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (Cmax)</measure>
    <time_frame>calculated over the period of timepoints at D1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (Tmax)</measure>
    <time_frame>calculated over the period of timepoints at D1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (AUC last)</measure>
    <time_frame>estimated over the period of timepoints at D1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter (AUC)</measure>
    <time_frame>extrapolated based on the period of timepoints at D1 of each study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time profile from time of standardized breakfast start (30 min after IMP injection) until 4 hours later for insulin, C-peptide and glucagon</measure>
    <time_frame>D1 at each period up to 4h30 after study drug injection (7 timepoints)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide (AVE0010)</intervention_name>
    <description>Pharmaceutical form:Solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Solution for injection&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male or female patients with type 2 diabetes mellitus, as defined by WHO (fasting&#xD;
             plasma glucose ≥ 7 mmol/L (126mg/dL) or 2 hours postprandial plasma glucose ≥ 11.1&#xD;
             mmol/L (200 mg/dL)), diagnosed for at least 1 year (adults) and at least 3 months for&#xD;
             paediatric population at the time of screening visit, with or without metformin&#xD;
             (stable dose ± 10 % for at least 4 weeks prior to randomization)&#xD;
&#xD;
          -  HbA1c ≥ 7% and ≤ 10% at screening&#xD;
&#xD;
          -  Age eligibility for paediatric population: ≥ 10 years and &lt;18 years with at least 3&#xD;
             patients below 15 years and no more than 3 patients aged between 16 and 18 years; Age&#xD;
             eligibility for adults: ≥ 18 and ≤ 65 years&#xD;
&#xD;
          -  For paediatric population:body weight &gt;50kg, BMI &gt;85th percentile for age and gender&#xD;
             and BMI ≤ 50 kg/m²&#xD;
&#xD;
          -  For adults: BMI &gt; 25 kg/m2 and ≤ 37 kg/m2&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  If female, pregnancy (defined as positive serum pregnancy test), breast-feeding&#xD;
&#xD;
          -  Diabetes other than type 2 diabetes&#xD;
&#xD;
          -  Positive test for insulinoma associated protein (IA2) and glutamic acid decarboxylase&#xD;
             (GAD) autoantibodies&#xD;
&#xD;
          -  Use of other oral or injectable antidiabetic or hypoglycemic agents other than&#xD;
             metformin (e.g., alpha glucosidase inhibitor, exenatide, DPP-IV inhibitors, insulin&#xD;
             etc.) within 3 months prior to the time of screening&#xD;
&#xD;
          -  Allergic reaction to any GLP-1 agonist in the past (e.g. exenatide, liraglutide) or to&#xD;
             metacresol&#xD;
&#xD;
          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,&#xD;
             stomach/gastric surgery, inflammatory bowel disease&#xD;
&#xD;
          -  Personal or family history of medullary thyroid cancer (MTC) or genetic conditions&#xD;
             that predispose to MTC (e.g., multiple endocrine neoplasia syndromes)&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>Puebla</city>
        <zip>72190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710002</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826001</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

